| "I am a woman and I am a world-class athlete. 
				The IAAF (International Association of Athletics Federations) 
				will not drug me or stop me from being who I am," the 
				28-year-old South African said in a statement after lodging the 
				appeal.
 In a case splitting opinion in women's sport, Semenya lost an 
				appeal to the Court of Arbitration for Sport (CAS) on May 1 
				which ruled the IAAF's rules were necessary for athletes with 
				differences in sexual development (DSDs) to ensure fair 
				competition.
 
 Semenya's statement added that she will ask the Swiss Federal 
				Supreme Court to set aside CAS's decision in its entirety, which 
				it said did not consider medical protocols and uncertain health 
				consequences of taking testosterone-reducing medication.
 
 Under the new regulations, female athletes with high natural 
				levels of testosterone wishing to compete in events from 400 
				meters to a mile must medically limit that level to under five 
				nmol/L, double the normal female range of below two nmol/L.
 
 Semenya has repeatedly stated she will not take medication to 
				comply with the regulations, which came into effect on May 8, 
				but she has also vowed to continue to compete in the 800 meters.
 
 Testosterone is a hormone that increases muscle mass, strength 
				and hemoglobin - which affects endurance.
 
 Semenya won her last competitive 800 meter race at a Diamond 
				League meeting in Doha on May 3 and has pledged to return to 
				Qatar to defend her world title in September, but the 
				regulations will not allow her to compete unless she takes 
				medication.
 
 Semenya, who also races 5,000 meters, could continue to compete 
				in longer distances not affected by the rule change but she has 
				vowed to continue her fight to stay competing in the 800 meters, 
				which she recently said was her calling.
 
 (Reporting by Richard Martin; Editing by Ed Osmond and Andrew 
				Cawthorne)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
				 |  |